文献速递免疫规划卫生政策与健康促进

布隆迪轮状病毒疫苗国家免疫规划的经济学分析

Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi.
PubMed 文献 · Vaccine · 2021-01-22

本研究构建马尔可夫模型,模拟布隆迪2019年出生队列5年内接种轮状病毒疫苗的临床与经济结局,并估算4种WHO预认证疫苗的ICER、净现值与预算影响。结果显示所有疫苗均具成本效果,其中三种从提供者和社会角度均极具成本效果,且所有项目均具成本效益。

要点

  • 四种WHO预认证轮状病毒疫苗均具成本效果(ICER<3倍人均GDP)。
  • Rotarix、Rotavac和Rotasiil从提供者和社会角度均极具成本效果(ICER<1倍人均GDP)。
  • 所有接种项目均具成本效益,净现值范围为5,214,912至11,135,997美元。

核心结论

  • 轮状病毒疫苗物有所值,可为布隆迪退出GAVI后的疫苗覆盖规划提供经济学证据。

研究设计与样本

  • 构建马尔可夫模型模拟布隆迪2019年出生队列5年内的临床与经济结局,并收集实证成本数据。

主要发现

  • 基础分析中所有四种WHO预认证轮状病毒疫苗均具成本效果(ICER<3倍人均GDP)。
  • Rotarix、Rotavac和Rotasiil从提供者和社会角度均极具成本效果(ICER<1倍人均GDP)。
  • 疫苗在价格分别上涨至5.09、3.16、3.89和2.69美元时仍极具成本效果。
  • 概率敏感性分析显示Rotarix、RotaTeq、Rotavac和Rotasiil具成本效果的概率分别为93.8%、27%、99.1%和92.7%。
  • 所有接种项目均具成本效益,净现值范围为5,214,912至11,135,997美元。

关键数值与推荐

  • 成本效果阈值:ICER<3倍人均GDP为具成本效果,ICER<1倍人均GDP为极具成本效果。
  • 按盈亏平衡价格估算的5年接种项目预算范围为42,249,498至53,487,935美元,低于2019年布隆迪GDP的2%。

临床怎么用

  • 可为布隆迪国家免疫规划中选择轮状病毒疫苗品牌及规划预算提供经济学依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Burundi, diarrhea is the third leading cause of mortality among children under five years of age. This study conducted an economic analysis of rotavirus vaccination program in Burundi. METHODS: A Markov model was constructed to simulate clinical and economic outcomes for the 2019 birth cohort for a period of 5 years. Empirical costing data were collected. ICER per episode averted, ICER per death averted, ICER per DALY averted, net present value, and budget impact were estimated for 4 brands of WHO pre-qualified rotavirus vaccines. One-way and probabilistic sensitivity analysis as well as threshold analysis were performed. RESULTS: For the base case, while all four WHO pre-qualified rotavirus vaccines were cost-effective (ICER < 3 GDP per capita), three of them (i.e. Rotarix, Rotavac and Rotasiil) were very cost-effective (ICER <1 GDP per capita) from both the provider and societal perspectives. The vaccines were still very cost-effective at a price increase of up to US$ 5.09, US$ 3.16, US$ 3.89, and US$ 2.69 for Rotarix, RotaTeq, Rotavac, and Rotasiil, respectively. Probabilistic sensitivity analysis indicated that vaccination programs with Rotarix, RotaTeq, Rotavac, and Rotasiil are cost-effective at a probability of 93.8%, 27%, 99.1%, and 92.7%, respectively. All vaccination programs were cost-beneficial with a net present value in the range of US$ 5,214,912 and US$ 11,135,997.The budget required to run the vaccination program, estimated with break-even prices, ranged between US$ 42,249,498 and US$ 53,487,935 for a 5-year time period. When compared to the GDP of Burundi in 2019, these are are less than 2%. CONCLUSION: The rotavirus vaccine is good value for money. Findings from this study offer evidence on potential economic benefits as well as the required budget for different rotavirus vaccination programs, which could be useful for future planning related to rotavirus vaccine coverage in Burundi after graduation from GAVI.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Niyibitegeka F, Riewpaiboon A, Youngkong S, et al. Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi. Vaccine. 2021. PMID: 33487467. doi:10.1016/j.vaccine.2021.01.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。